page contents

Tuesday, 7 May 2013

Breast Cancer Treatment

Breast Cancer Treatment Biography


    Active Specific Immunotherapy (ASI) is one of the most recent advances in cancer tumour therapy in this modern regenerative and integrative medical field. This concept modulates the immune system to achieve an anti tumour response with tumour-associated antigens as the immunising materials. It potentially helps fight cancer and other diseases such as autoimmune disease. It is based on the fact that the immune system is the best tool in combating the disease. Recent clinical studies reflect the effectiveness of Immunotherapy in combination with complementary therapies as a potential approach to specifically target cancer cells without causing any harm to the immune system

    One of the major benefits of Immunotherapy is that it does not display any form of toxicity. In addition it offers a different mode of attack on the tumour by strengthening the immune system.

    Active Specific Immunotherapy (ASI) a patented therapy by the Edith Liebergeld Institute in Germany and was developed by Dr Rudolph Pekar, an Austrian renowned Cell Therapist and expert on bioelectrotherapy. The therapy is a form of non-invasive complementary therapy/alternative therapy to improve malignant conditions at the early stages of the diseases. Recent immunologic studies have shown that cancer is not only a cellular disorder triggered by false genetic information but more of a problem of immunology, thus; making ASI a good choice as an Immunotherapy. It is meant to bring relief from danger of disease’s relapse by acting as “anti-idiotype antibody”. It is delivered to the patient as vaccination in 30 vials of 1.1 cc. each.

No comments:

Post a Comment